The Industry Theaters take place in the Exhibit Hall, which is open from 10:30 a.m. to 4 p.m. today.
Photo by RC Photographic Productions
Have lunch while listening to the latest clinical updates from supporting companies related to pulmonary, critical care, or sleep medicine. Daily Industry Theaters and Mini Theaters are available today, Monday, and Tuesday in the Exhibit Hall. All include a complimentary boxed lunch provided by the ATS (while quantities last).
Today
Noon to 12:45 p.m.
ATS Industry Theater 1
Time to Reevaluate? An Evidence-Based Discussion on the Use of a LABA in COPD
Current GOLD pharmacologic treatment guidelines position bronchodilators as central to COPD management. A review of market dynamics and published literature suggest that certain notions may impact the use of long-acting ß2-agonist in COPD. This interactive presentation will compel the audience to consider IF and HOW clinical trial results for a long-acting ß2-agonist support its use for maintenance bronchodilator therapy in COPD. Esteemed faculty will discuss key topics to be considered when making treatment choices for patients with COPD.
Speaker(s): Richard Casaburi, PhD, MD, Los Angeles Biomedical Research Institute at Harbor-University of California, Los Angeles, Medical Center, Torrance; and Sanjay Sethi, MD, University of Buffalo, State University of New York
Company: Novartis Pharmaceuticals Corporation
Noon to 12:45 p.m.
ATS Industry Theater 2
FeNO: Let’s Clear the Air
Current guidelines have been established on how FeNO measurements should be used and interpreted in clinical practice. At this session, experts will review how they utilize FeNO measurements made with the NIOX MINO® device to help assess and monitor their patients with asthma.
Company: Aerocrine
Noon to 12:45 p.m.
ATS Industry Theater 3 (International)
Small Airways in Respiratory Disease: Prevalence, Diagnosis, and Treatment
This lecture will illustrate to the audience the most updated evidence concerning the detection and prevalence of small airways impairment in clinical practice. Furthermore, new data related to recent trials that assess the efficacy of small particle formulations that are able to reach and treat small airways will be presented.
Speaker(s): Leonardo M. Fabbri, MD, professor of respiratory medicine and director, department of oncology haematology and respiratory diseases, University of Modena and Reggio Emilia, Modena, Italy; and Peter J. Barnes, FRS, FMedSci, professor and head of respiratory medicine, Imperial College London Airway Disease Section, National Heart and Lung Institute, London
Company: Chiesi Farmaceutici SpA
Open to Non-U.S. attendees only.
Noon to 12:20 p.m.
ATS Mini Industry Theater
Gilead PAH 2013 Mini Theater
Company: Gilead Sciences Inc.
12:30 to 12:50 p.m.
ATS Mini Industry Theater
The Role of Maintenance Nebulization for the Treatment of COPD: Perforomist® (formoterolfumarate) Inhalation Solution
Company: Mylan Specialty L.P.
Monday
Noon to 12:45 p.m.
ATS Industry Theater 1
Is Oral Therapy Enough for Patients with PAH? When to Add More
Join a panel of experts for an interactive discussion regarding treatment strategy and when to add more therapy to help pulmonary arterial hypertension patients manage their disease.
Topics: Patient identification, timing for adding therapy, why targeting a second critical pathway should be considered, inhaled prostacyclin MOA, and efficacy.
Lunch provided.
Speaker(s): Paul Forfia, MD director, pulmonary hypertension and right heart failure program, Temple University Medical Center, Philadelphia; and Aaron Waxman, MD, PhD, director, pulmonary vascular disease program, Brigham and Women’s Hospital, Harvard Medical School, Boston
Company: United Therapeutics Corporation
Noon to 12:45 p.m.
ATS Industry Theater 2
Bronchial Thermoplasty: A Paradigm Shift in the Treatment of Severe Asthma
Bronchial Thermoplasty, delivered by the Alair™ System, is a safe and minimally invasive outpatient procedure clinically proven to provide a long-lasting reduction in asthma exacerbations for patients with severe asthma. Please join us to learn more about this additional treatment option and the appropriate patients who may benefit from this procedure.
Speaker(s): Felix J.F. Herth, MD, PhD, chairman and professor, Department of Pneumology and Critical Care Medicine, Thoraxklinik, University of Heidelberg, Germany; Ian Pavord, MB, honorary professor of medicine, Department of Respiratory Medicine, Glenfield Hospital, Leicester, United Kingdom; Michel Wechsler, MD, director of asthma, National Jewish Health, Denver; and Gerard Cox, MB, director, Division of Respirology, and professor of medicine, McMaster University, Hamilton, Canada
Company: Boston Scientific Corporation
Noon to 12:45 p.m.
ATS Industry Theater 3
Improving Lung Function in COPD Patients: A Treatment Update
This program will provide insights into the clinical course of COPD, discuss the role of bronchodilation in the management of COPD, and present a treatment option that improves lung function in COPD patients.
Company: Forest Pharmaceuticals, Inc.
Noon to 12:20 p.m.
ATS Mini Industry Theater
Gilead PAH 2013 Mini Theater
Company: Gilead Sciences Inc.
12:30 to 12:50 p.m.
ATS Mini Industry Theater
Challenging the Management of COPD: Ruling Out Alpha-1
This presentation will help health care professionals understand the importance of ruling out alpha-1 antitrypsin deficiency, a common genetic cause of COPD, in all their COPD patients. Participants will learn how easy it is to test, as well as the strategies for managing alpha-1 patients and the support available to providers and patients if testing identifies a patient in their practice.
Company: Grifols USA
Tuesday
Noon to 12:45 p.m.
ATS Industry Theater 1
Remodeling the Dialogue: Optimizing the Parenteral Conversation and Increasing Patient Understanding
Join Vallerie McLaughlin, MD, for a presentation and live discussion about an evidence-based initiative to uncover and optimize the provider-patient conversation regarding parenteral therapy for PAH. Dr. McLaughlin will review research findings, including patient barriers to starting parenteral therapy and techniques that can be implemented to address these patient concerns. Lunch will be provided.
Company: United Therapeutics Corporation
Noon to 12:45 p.m.
ATS Industry Theater 2 (International)
Improving COPD Patient Outcomes with Once-Daily Bronchodilators
The aim of this Novartis-sponsored industry theatre is to highlight the importance of managing symptoms, exacerbations, and health status in COPD. The industry theatre will focus on the central role played by long-acting bronchodilators in the context of the GOLD 2013 strategy document. Clinical evidence will be presented on the use of indacaterol, a once-daily long-acting ß2-agonist, and glycopyrronium, a new inhaled once-daily long-acting anticholinergic, in the treatment of COPD.
Speaker(s): Ken Chapman, professor and chair, University of Toronto; David Singh, professor, University Hospital of South Manchester, United Kingdom; and Paul Jones, professor, St George’s University of London
Company: Novartis Pharma AG
This Novartis-sponsored industry theater is only open to EU physicians.
Noon to 12:45 p.m.
ATS Industry Theater 3
Reducing the Risk of COPD Exacerbations: Proactive Management of Patients at Risk
This program will discuss the prevalence and impact of COPD exacerbations, review the relevance of proactive exacerbation prevention, and present a treatment strategy to reduce the risk of COPD exacerbations.
Company: Forest Pharmaceuticals, Inc.
Noon to 12:20 p.m.
ATS Mini Industry Theater
Nebulization for the Maintenance Treatment of COPD: When, Why, and Where?
Company: Mylan Specialty L.P.